血清SIRT1表达对丙戊酸钠治疗癫痫患者疗效的影响

杨艳萍; 何蝶; 周振; 曾庆繁; 彭红英; 赵立新; 马丹

doi:10.6039/j.issn.1001-0408.2022.23.13

您当前的位置：

首页 >

文章列表页 >

血清SIRT1表达对丙戊酸钠治疗癫痫患者疗效的影响

药物与临床 | 更新时间：2023-02-22

- 血清SIRT1表达对丙戊酸钠治疗癫痫患者疗效的影响
- Effects of the expression of serum SIRT1 on therapeutic efficacy of sodium valproate in the treatment of epilepsy patients
- 中国药房 2022年33卷第23期页码：2886-2890
- 作者机构：
  
  1.贵州医科大学附属白云医院药剂科，贵阳　550014
  2.贵州医科大学附属医院药剂科，贵阳　550004
  3.贵州医科大学附属白云医院麻醉科，贵阳　550014
  4.贵州医科大学附属白云医院肾内科，贵阳　550014
  5.贵州医科大学附属白云医院中医科，贵阳　550014
  6.贵州医科大学附属医院血液内科，贵阳　550004
- 作者简介：
  
  硕士。研究方向：临床药学。E-mail：yyp129343@163.com
  副主任技师，硕士生导师，博士。研究方向：医院药学。E-mail：readying100@163.com
- 基金信息：
  
  国家自然科学基金资助项目(82003835);贵州省科技计划项目（No.黔科合基础-ZK〔2022〕一般412,No.黔科合支撑〔2020〕4Y239号）;贵州省卫生健康委科学技术基金项目(gzwkj2021-468)
- DOI：10.6039/j.issn.1001-0408.2022.23.13
  中图分类号： R971;R742.1
- 纸质出版日期：2022-12-15，
  
  收稿日期：2022-06-07，
  
  修回日期：2022-08-23，
扫描看全文
杨艳萍,何蝶,周振等.血清SIRT1表达对丙戊酸钠治疗癫痫患者疗效的影响 ^Δ[J].中国药房,2022,33(23):2886-2890.

YANG Yanping,HE Die,ZHOU Zhen,et al.Effects of the expression of serum SIRT1 on therapeutic efficacy of sodium valproate in the treatment of epilepsy patients[J].ZHONGGUO YAOFANG,2022,33(23):2886-2890.
杨艳萍,何蝶,周振等.血清SIRT1表达对丙戊酸钠治疗癫痫患者疗效的影响 ^Δ[J].中国药房,2022,33(23):2886-2890. DOI： 10.6039/j.issn.1001-0408.2022.23.13.

YANG Yanping,HE Die,ZHOU Zhen,et al.Effects of the expression of serum SIRT1 on therapeutic efficacy of sodium valproate in the treatment of epilepsy patients[J].ZHONGGUO YAOFANG,2022,33(23):2886-2890. DOI： 10.6039/j.issn.1001-0408.2022.23.13.

摘要

目的

探索血清Sirtuin-1（SIRT1）表达对丙戊酸钠（VPA）治疗癫痫患者疗效的影响。

方法

选择2021年3－10月贵州医科大学附属白云医院就诊的54例癫痫患者为研究对象，并同期选择50例健康者作为基线参考样本。将SIRT1 mRNA相对表达水平低于基线的患者作为SIRT1低表达治疗组，高于基线者作为SIRT1高表达治疗组。所有患者给予低剂量VPA（12 mg/kg或每日约600 mg）治疗3个月，并评价临床疗效；对癫痫控制无效的患者增加VPA药物剂量（15 mg/kg或每日约800 mg）再治疗3个月，作为SIRT1高表达加量组和SIRT1低表达加量组，并评价临床疗效。检测患者治疗3个月、加量治疗3个月后的血药浓度和肝功能指标。

结果

治疗前，54例癫痫患者中有31例SIRT1低表达，23例SIRT1高表达。低剂量VPA治疗3个月后，在VPA有效血药浓度范围内，SIRT1高表达治疗组患者的有效控制率明显低于SIRT1低表达治疗组（

＜0.05）；加量治疗3个月后，SIRT1高表达加量组患者的有效控制率显著高于SIRT1高表达治疗组（

＜0.05）。VPA治疗期间，患者肝功能指标未见异常。

结论

在VPA有效血药浓度范围内治疗癫痫时，血清SIRT1高表达患者的癫痫可能更难控制；增加VPA剂量后，可提高癫痫发作的有效控制率。

Abstract

OBJECTIVE

To explore the effects of the expression of serum Sirtuin-1 （SIRT1） on therapeutic efficacy of sodium valproate （VPA） in the treatment of epilepsy patients.

METHODS

Fifty-four epileptic patients were collected from the Affiliated Baiyun Hospital of Guizhou Medical University from Mar. to Oct. 2021 as the research objects， and fifty healthy people were also collected during corresponding period as baseline reference samples. The patients whose relative mRNA expression of SIRT1 was lower than the baseline were selected as SIRT1 low-expression treatment group， and the patients whose that expression was higher than the baseline as SIRT1 high-expression treatment group. All patients were treated with low dose （12 mg/kg or about 600 mg/day） of VPA for 3 months， and the clinical efficacy was evaluated. The dosage of VPA in patients with ineffective epilepsy control should be increased to 15 mg/kg or about 800 mg/day for another 3 months as SIRT1 high-expression intensive treatment group and SIRT1 low-expression intensive treatment group. Clinical efficacies were evaluated. The blood concentration and liver function indexes of the patients were detected after 3 months of treatment and 3 months of intensive treatment.

RESULTS

Before treatment， among 54 epileptic patients， 31 epileptic patients had low expression of SIRT1， and 23 had high expression of SIRT1. After 3 months of low-dose VPA treatment， within effective blood concentration of VPA， effective control rate of patients in SIRT1 high-expression treatment group was significantly lower than SIRT1 low-expression treatment group （

＜0.05）. After 3 months of intensive treatment， the effective control rate of patients SIRT1 high-expression intensive treatment group was significantly higher than SIRT1 high expression treatment group （

＜0.05）. No abnormality was found in liver function indexes during VPA treatment.

CONCLUSIONS

Epilepsy in patients with high expression of serum SIRT1 may be more difficult to control when VPA is within the effective blood concentration range； when the VPA dose is effectively increased， the effective control rate of epilepsy can be improved.

关键词

Sirtuin-1癫痫丙戊酸钠血药浓度监测肝功能

Keywords

epilepsysodium valproateblood concentration monitoringliver function

references

MEGIDDO I，COLSON A，CHISHOLM D，et al. Health and economic benefits of public financing of epilepsy treatment in India：an agent-based simulation model[J]. Epilepsia，2016，57（3）：464-474.

LÖSCHER W，POTSCHKA H，SISODIYA S M，et al. Drug resistance in epilepsy：clinical impact，potential mechanisms，and new innovative treatment options[J]. Pharmacol Rev，2020，72（3）：606-638.

MISHRA M K，KUKAL S，PAUL P R，et al. Insights into structural modifications of valproic acid and their pharmacological profile[J]. Molecules，2021，27（1）：104.

牛茜，崔华伟，王维平.癫痫及抗癫痫药对癫痫患者认知功能的影响[J].河北医科大学学报，2018，39（3）：356-359.

中国抗癫痫协会.临床诊疗指南：癫痫病分册：2015修订版[M].北京：人民卫生出版社，2015：113.

ROMOLI M，MAZZOCCHETTI P，D’ALONZO R，et al. Valproic acid and epilepsy：from molecular mechanisms to clinical evidences[J]. Curr Neuropharmacol，2019，17（10）：926-946.

VIDAURRE J，GEDELA S，YAROSZ S. Antiepileptic drugs and liver disease[J]. Pediatr Neurol，2017，77：23-36.

CHATEAUVIEUX S，MORCEAU F，DICATO M，et al. Molecular and therapeutic potential and toxicity of valproic acid[J]. J Biomed Biotechnol，2010，2010：479364.

OSÓRIO C M，LIN K，GUARNIERI R，et al. Mitochondrial respiratory chain complex enzyme activities of limbic structures and psychiatric diagnosis in temporal lobe epilepsy patients：preliminary results[J]. CNS Neurosci Ther，2017，23（8）：700-702.

HOUTKOOPER R H，PIRINEN E，AUWERX J. Sirtuins as regulators of metabolism and healthspan[J]. Nat Rev Mol Cell Biol，2012，13（4）：225-238.

CHUANG Y C，CHEN S D，JOU S B，et al. Sirtuin 1 regulates mitochondrial biogenesis and provides an endoge- nous neuroprotective mechanism against seizure-induced neuronal cell death in the Hippocampus following status epilepticus[J]. Int J Mol Sci，2019，20（14）：E3588.

MISHRA P，MITTAL A K，KALONIA H，et al. SIRT1 promotes neuronal fortification in neurodegenerative di- seases through attenuation of pathological hallmarks and enhancement of cellular lifespan[J]. Curr Neuropharmacol，2021，19（7）：1019-1037.

HALL A M，BRENNAN G P，NGUYEN T M，et al. The role of SIRT1 in epileptogenesis[J]. eNeuro，2017，4（1）：301-316.

陈永平，谢运兰，王衡，等. SIRT1在癫痫患者及大鼠脑组织中的表达与活性[J].南方医科大学学报，2013，33（4）：528-532.

李烈权.丙戊酸钠治疗癫痫的血药浓度监测与分析[J].中国临床药理学杂志，2013，29（8）：631-632.

VIANA-MATTIOLI S，NUNES P，CAVALLI R，et al. Analysis of SIRT1 expression in plasma and in an in vitro model of preeclampsia[J]. Oxid Med Cell Longev，2020，2020：4561083.

曾艳，刘立丽，闫素英.丙戊酸钠血清浓度接近或超过治疗浓度范围上限患者的肝功能、血常规结果分析[J].中国药物应用与监测，2013，10（2）：66-70.

中华医学会.临床诊疗指南：癫痫病分册（2015年修订版）[M].北京：人民卫生出版社，2015：44-46.

LI M，WANG C Y，RONG B X. Effects of valproic acid on skeletal metabolism in children with epilepsy：a systematic evaluation and meta-analysis based on 14 studies[J]. BMC Pediatr，2020，20（1）：97.

ABUALHASAN M，ODEH N W，YOUNIS G N，et al. Analytical method development for sodium valproate through chemical derivatization[J]. Int J Anal Chem，2020，2020：5672183.

罗媛，张慧明. 164例/次丙戊酸钠血药浓度监测影响因素和安全用药分析[J].当代医学，2020，26（3）：104-105.

TSENG Y J，HUANG S Y，KUO C H，et al. Safety range of free valproic acid serum concentration in adult patients[J]. PLoS One，2020，15（9）：e0238201.

ZHOU Y，WANG S H，LI Y X，et al. SIRT1/PGC-1α signaling promotes mitochondrial functional recovery and reduces apoptosis after intracerebral hemorrhage in rats[J]. Front Mol Neurosci，2018，10：443.

LIU P，ZOU D，YI L，et al. Quercetin ameliorates hypobaric hypoxia-induced memory impairment through mitochondrial and neuron function adaptation via the PGC-1α pathway[J]. Restor Neurol Neurosci，2015，33（2）：143-157.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

个体化肠外营养支持对比预混肠外营养配方对急性肾损伤患者肝功能的影响

复方甘草酸苷改善酒精性肝病患者肝功能的Meta分析

桦褐孔菌多糖对急性酒精性肝损伤模型大鼠的保护作用研究

117例抗结核药物致肝功能损害的临床分析

门冬氨酸鸟氨酸对肝部分切除术后缺血再灌注损伤的保护作用